Climb Bio, Inc. Files Q1 2025 10-Q
Ticker: CLYM · Form: 10-Q · Filed: May 14, 2025 · CIK: 1768446
Sentiment: neutral
Topics: 10-Q, financials, marketable-securities
TL;DR
Climb Bio's Q1 2025 10-Q is in. Check their marketable securities.
AI Summary
Climb Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Eliem Therapeutics, Inc., reported on its financial status, including marketable securities. Key dates mentioned include the filing date of May 14, 2025, and the reporting period of Q1 2025.
Why It Matters
This filing provides investors with an update on Climb Bio's financial health and operations for the first quarter of 2025, including details on their investments in marketable securities.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new risks indicated.
Key Players & Entities
- Climb Bio, Inc. (company) — Filer
- Eliem Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250514 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250514.
What was Climb Bio, Inc. formerly known as?
Climb Bio, Inc. was formerly known as Eliem Therapeutics, Inc., with a date of name change on 20190219.
What is Climb Bio, Inc.'s Standard Industrial Classification (SIC) code?
Climb Bio, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What types of marketable securities does Climb Bio, Inc. hold?
The filing mentions various marketable securities including Money Market Funds, Corporate Bond Securities, US Government Agencies Debt Securities, and others categorized under ShortTermMarketableSecurities and LongTermMarketableSecurities.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Climb Bio, Inc. (CLYM).